References
- 1. Scalfari A, Neuhaus A, Degenhardt A et al - The natural history of multiple sclerosis: a geographically based study 10: relapses and long term disability. Brain. 2010;133:1914-29.
- 2. Ciccarelli O, Thompson A - Multiple sclerosis in 2015: Managing the complexity of multiple sclerosis. Nat Rev Neurol. 2016;12:70-2.
- 3. Tremlett H, Yinshan Z, Devonshire V - Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14:314-24.
- 4. Isaacs A, Lindenmann J - Virus Interference: I. The Interferon. Proc R Soc Lond B Biol Sci. 1957;147:258-67.
- 5. Panitch HS, Hirsch RL, Schindler J et Johnson KP - Treatment of multiple sclerosis with gamma interferon: exacerbations associated with the activation of the immune system. Neurology. 1987;37:1097-102.
- 6. Kappos L, Polman CH, Freedman MS, et al - Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-9.
- 7. European Study Group on Interferon Beta-1b in Secondary Progressive MS - Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;1491-7.
- 8. Filippini G, Munari L, Incorvaia B, et al - Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361:545–52.
- 9. Kappos L, Polman C, Pozzilli C, et al - Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology. 2001;57:1969-75.
- 10. Kappos L, Freedman MS, Polman CH, et al - Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENFIT trial. Lancet Neurol. 2009;8:987-997.
- 11. Polman CH, Reingold SC, Banwell B et al - Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
- 12. Kurtzke JF - Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-52.
- 13. Confavreux C, Vukusic S, Thibault M et al. – Relapses and progression of disability in multiple sclerosis. The New England Journal of Medicine. 2000; 343:1430-8.
- 14. IFNB Multiple sclerosis study group and the University of British Columbia. MS/MRI Analysis group - Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995; 45:1277-85.
- 15. Steinman L - Multiple sclerosis: a two stage disease. Nat Immunol. 2001;2:762-4.
- 16. Leray E, Yaouaq J, Le Page E et al - Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010.1900-13.
- 17. Paolicelli D, Direnzo V, Trojano M - Review of interferon beta 1b in the treatment of early and relapsing multiple sclerosis, Biologics. 2009;3:369-76.
- 18. Barcutean LI, Romaniuc A, Maier S et al - Clinical and serological biomarkers of treatment’s response in patients treated continuosly with interferon β-1b for more than a decade. CNS Neurol Disord Drug Targets. 2018. DOI: 10.2174/1871527317666180917095256. E-pub ahead of print.10.2174/1871527317666180917095256.E-pubahead
- 19. Harbo JH, Gold R, Tintore M - Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord. 2013; 6:237-48.
- 20. Dunn SE, Gunde E, Lee H - Sex -based differences in multiple sclerosis (MS): Part II: Rising incidence of multiple sclerosis women and the vulnerability of men to progression of this disease. Current Topics in behavioural neurosciences. 2015;26:57-86.
- 21. Bell J, Lathrop G - Multiple loci for multiple sclerosis. Nat Genet. 13;1996:377-8.
- 22. Oksenberg J, Barcellos L, Cree L et al - Mapping multiple sclerosis susceptibility to the HLA-DR locus in African americans. Am J Hum Genet. 2004;74:160-7.
- 23. Tremlett H, Paty D, Devonshire V - Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006. 24; 66:172-7.
- 24. Weinshenker BG, Rice GP, Nosworthy JH - The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain. 1991; 114:1045-56.
- 25. Palace J, Duddy M, Lawton M et al – Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. J Neurol Neurosurg Psychiatry. 2018; DOI: 10.1136/jnnp-2018-318360.
- 26. Lublin FD, Baier M, Cutter G - Effect on relapses on developmental of residual deficit in multiple sclerosis. Neurology. 2003; 9:1528-1532.
- 27. Young PJ, Leaderer C, Eder K et al - Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology 2006; 12: 804-8.
- 28. Kappos L, Freedman MS, Polman CH, et al - Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370;389-97.
- 29. Panitch H, Miller A, Paty D, Weinshenker B - Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788-1795.
- 30. Cree BA, Gourraud PA, Oksenberg JR, et al - Long term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80:499-510.
- 31. Vukusic S, Confavreux C - Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci. 2003;206:135-7.
- 32. Confavreux C, Vuksic S - Age at disability milestones in multiple sclerosis. Brain. 2006;129:595-605.
- 33. Trojano M, Pellegrini F, Fuiani A et al - New natural history of Interferon-β-treated relapsing multiple sclerosis. Ann Neurol. 2007;61:300-6.
- 34. Bergamaschi R - Prognostic factors in multiple sclerosis. Int Rev Neurobiol. 2007;79:423-47.
- 35. Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC - Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol. 2009; 5:672-82.
- 36. Visscher B, Liu KS, Clark VA, Detels R, Malmgren RM, Dudley JP - Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol Scand. 1984;70:321-28.
- 37. Razzolini L, Portaccio E, Stromillo ML et al - The dilemma of benign multiple sclerosis: Can we predict the risk of losing the “benign status”? A 12-year follow-up study. Mult Scler Relat Disord. 2018; DOI: 10.1016/j.msaed.2018.08.011 Epub ahead of print.10.1016/j.msaed.2018.08.011Epubahead
- 38. Reader AT, Ebers GC, Traboulsee A, et al - Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010;74:1877-85.
- 39. Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS – Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge. Expert Rev Clin Immunol. 2018;14:137-53.
- 40. Baum K, O’Leary C, Coret Ferrer F, et al - Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b. Mult Scler. 2007;13:1153-60.
- 41. Harris C, Billisberger K, Tillotson L et al - Injection-site pain in patients with multiple sclerosis: interferon beta-1b versus interferon beta-1a. Int J MS Care. 2005/2006;7:132-6.